1. Home
  2. REPL vs VTLE Comparison

REPL vs VTLE Comparison

Compare REPL & VTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • VTLE
  • Stock Information
  • Founded
  • REPL 2015
  • VTLE 2006
  • Country
  • REPL United States
  • VTLE United States
  • Employees
  • REPL N/A
  • VTLE N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • VTLE
  • Sector
  • REPL Health Care
  • VTLE
  • Exchange
  • REPL Nasdaq
  • VTLE Nasdaq
  • Market Cap
  • REPL 757.8M
  • VTLE 650.9M
  • IPO Year
  • REPL 2018
  • VTLE 2011
  • Fundamental
  • Price
  • REPL $9.35
  • VTLE $16.13
  • Analyst Decision
  • REPL Strong Buy
  • VTLE Hold
  • Analyst Count
  • REPL 7
  • VTLE 11
  • Target Price
  • REPL $20.83
  • VTLE $26.38
  • AVG Volume (30 Days)
  • REPL 1.1M
  • VTLE 1.5M
  • Earning Date
  • REPL 08-07-2025
  • VTLE 08-06-2025
  • Dividend Yield
  • REPL N/A
  • VTLE N/A
  • EPS Growth
  • REPL N/A
  • VTLE N/A
  • EPS
  • REPL N/A
  • VTLE N/A
  • Revenue
  • REPL N/A
  • VTLE $1,982,155,000.00
  • Revenue This Year
  • REPL N/A
  • VTLE $3.26
  • Revenue Next Year
  • REPL N/A
  • VTLE N/A
  • P/E Ratio
  • REPL N/A
  • VTLE N/A
  • Revenue Growth
  • REPL N/A
  • VTLE 16.77
  • 52 Week Low
  • REPL $6.44
  • VTLE $12.30
  • 52 Week High
  • REPL $17.00
  • VTLE $47.80
  • Technical
  • Relative Strength Index (RSI)
  • REPL 49.55
  • VTLE 41.84
  • Support Level
  • REPL $8.92
  • VTLE $18.60
  • Resistance Level
  • REPL $9.93
  • VTLE $22.10
  • Average True Range (ATR)
  • REPL 0.52
  • VTLE 1.15
  • MACD
  • REPL -0.08
  • VTLE -0.37
  • Stochastic Oscillator
  • REPL 22.40
  • VTLE 4.92

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About VTLE Vital Energy Inc. par value $0.01 per share

Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.

Share on Social Networks: